Adults 18 to 44, female only, with Mobile Phone Use or Hiv. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Retention RatePrimary· 4 months
Feasibility is assessed with the retention rate of participants in each study arm. Quantitative survey and qualitative interview data to determine acceptability of both the mobile app and the control condition.
Group
Value
95% CI
In-the-kNOW Mobile App.
20
Control Condition.
24
App User Retention RatePrimary· 4 months
App user retention rate was calculated among participants only in the intervention group. App user retention was measured by comparing the number of first-time app opens to the number of app removals.
Group
Value
95% CI
In-the-kNOW Mobile App.
70.03
System Usability Scale (SUS)Primary· 4 months
The System Usability Scale (SUS) is a validated industry-standard scale used to evaluate a variety of products and services, including websites, mobile phones, computer software, and more. It is a quick, 10-item questionnaire for gauging perceived usability, resulting in a score from 0-100, where higher is better, with 68 as the average benchmark, and scores above 80 considered excellent; it's calculated by summing adjusted responses to positive/negative statements. Lower scores indicate low usability, and higher scores indicate good usability.
\*Only participants in the treatment group recei
Group
Value
95% CI
In-the-kNOW Mobile App.
63.25
± 13.54
Impact ScalePrimary· 4 months
Impact is evaluated using three items that assess how the SavvyHER app influences Black women's quality of life and their sexual and reproductive health. Items prompt participants to rate their agreement with statements such as "I think SavvyHER will be a positive addition to sexual and reproductive health resources for Black women" and "I think SavvyHER will improve the Quality of Life for Black women," with responses on a scale from "strongly disagree" (1) to "strongly agree" (5). Scores were calculated by averaging the responses. Impact scores ranged from 1 to 5, where 1 indicates the least
Group
Value
95% CI
In-the-kNOW Mobile App.
4.19
± 0.71
Perceived Usefulness (PU) ScalePrimary· 4 months
Perceived usefulness (PU) is defined as the extent to which a person believes that using a system or tool will help in reaching their goals. The PU of SavvyHER was determined from participants' responses to nine survey items assessing the app's impact on their quality of life and health management. Survey items used 5-point Likert scales, ranging from "strongly disagree" (1) to "strongly agree" (5). These scores are calculated by averaging the responses across PU items. PU scores ranged from 1 to 5, with higher scores indicating a more positive perception of the technology being evaluated.
Group
Value
95% CI
In-the-kNOW Mobile App.
3.54
± 0.63
Perceived Ease of Use (PEOU) ScalePrimary· 4 months
Perceived ease of use (PEOU) is the extent to which a system or tool is easy to learn and use.
PEOU is assessed using five survey items rated on a 5-point Likert scale that ask about people's experiences learning to operate a technological system or tool. Sample items prompt participants to rate their agreement with statements such as "Learning to operate SavvyHER is easy for me" and "It is easy for me to become skillful at using SavvyHER," with responses on a scale from "strongly disagree" (1) to "strongly agree" (5). Scores were calculated by averaging responses across PEOU items. PEOU scor
Group
Value
95% CI
In-the-kNOW Mobile App.
3.69
± 0.58
Number of Home Test Kits Ordered by Participants.Secondary· 4 months
The research team will measure HIV testing by counting the number of home test kits ordered by participants and receiving HIV test results from TBD Health. TBD Health partnered with the research team on at-home testing, laboratory work, and linking participants to care. Only participants in the treatment arm had access to at-home HIV testing; control participants did not.
Group
Value
95% CI
In-the-kNOW Mobile App.
3
Number of Participants Indicating Intention to Start PrEPSecondary· 4 months
Participants were asked about their intention to initiate PrEP during the 4-month study period using a post-test survey. Intention was assessed through a series of statements rated on a 5-point Likert scale (from 'definitely not' to 'definitely'
Do you plan on using PrEP to reduce your risk of getting HIV in the next 3 months?
Group
Value
95% CI
In-the-kNOW Mobile App.
8
Control Condition.
12
In-the-kNOW Mobile App.
11
Control Condition.
9
In-the-kNOW Mobile App.
5
Control Condition.
5
In-the-kNOW Mobile App.
2
Control Condition.
1
Do you plan on using PrEP to reduce your risk of getting HIV in the next 12 months?
Group
Value
95% CI
In-the-kNOW Mobile App.
5
Control Condition.
9
In-the-kNOW Mobile App.
14
Control Condition.
10
In-the-kNOW Mobile App.
5
Control Condition.
6
In-the-kNOW Mobile App.
1
Control Condition.
1
Do you plan to talk with your health provider about PrEP?
Group
Value
95% CI
In-the-kNOW Mobile App.
5
Control Condition.
5
In-the-kNOW Mobile App.
11
Control Condition.
13
In-the-kNOW Mobile App.
5
Control Condition.
5
In-the-kNOW Mobile App.
4
Control Condition.
4
Number of Participants Who Agreed With Statements About PrEP InitiationSecondary· 4 months
Participants were asked to select the statement that best reflected their attitude toward initiating PrEP from a predefined list of options.
I am ready to start taking PrEP for HIV prevention as soon as possible
Group
Value
95% CI
In-the-kNOW Mobile App.
1
Control Condition.
2
I have no intention of using PrEP for HIV prevention
Group
Value
95% CI
In-the-kNOW Mobile App.
19
Control Condition.
18
I am considering taking PrEP for HIV prevention, but I'm not ready to take action
Group
Value
95% CI
In-the-kNOW Mobile App.
6
Control Condition.
8
Missing
Group
Value
95% CI
In-the-kNOW Mobile App.
2
Control Condition.
0
Number of Participant's Who Initiated PrEP TreatmentSecondary· 4 months
The research team asked participants about their PrEP initiation. Response options were yes/no if participants had started PrEP by the end of the study period.
Group
Value
95% CI
In-the-kNOW Mobile App.
0
Control Condition.
0
Number of Enrolled Participants by Recruiting SourceSecondary· 4 months
Enrolled participants were asked how they heard about the study, allowing researchers to determine which method yielded the largest number of enrolled individuals.
Group
Value
95% CI
In-the-kNOW Mobile App.
21
Control Condition.
16
In-the-kNOW Mobile App.
0
Control Condition.
0
In-the-kNOW Mobile App.
1
Control Condition.
0
In-the-kNOW Mobile App.
0
Control Condition.
0
Number of Participants Reporting Smartphone OwnershipSecondary· 4 months
Participants who owned/used their smartphones for the intervention.
Group
Value
95% CI
In-the-kNOW Mobile App.
28
Control Condition.
28
Sponsor's own description
Black women have a significantly higher risk of acquiring HIV compared to their non-Black counterparts.
The purpose of this study is to refine and test a mobile HIV Prevention and Reproductive Health app developed specifically for Black women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06277232 — Nutrition Care in Patients Living With Chronic Pain
· NA
· recruiting
NCT06096272 — Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
· NA
· recruiting
NCT06731972 — The Impact of Using Mobile Games on Rehabilitation Outcomes in Thumb Rehabilitation
· NA
· recruiting
NCT06316804 — Mobile Mental Health Stigma Reduction Intervention Among Black Adults
· NA
· recruiting
NCT05907005 — Instant Message-delivered Early Psychological Intervention in Stroke Family Caregivers
· NA
· recruiting
Other Emory University trials
Trials by the same sponsor.
NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study
· NA
· withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
· NA
· not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose
· NA
· not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 16 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05080972.